Literature DB >> 2823934

Tumor necrosis factor: receptors on hematopoietic cells.

R Munker1, J DiPersio, H P Koeffler.   

Abstract

Tumor necrosis factor (TNF) is a monokine that is cytotoxic/cytostatic for a variety of tumor cells and has multiple effects on normal cells. We demonstrate that normal and malignant human myeloid cells express a single class of high-affinity receptors (400 to 1,900 per cell, KD 20 to 90 pmol/L) for TNF. Mitogen-stimulated lymphocytes have a similar number of TNF receptors, whereas resting lymphoid cells have fewer receptors. RBCs and platelets have no detectable TNF receptors. No correlation is observed between the receptor number, receptor affinity, and the cytotoxic effect of TNF on myeloid cell lines. Significant cytotoxic effects of TNF on the most sensitive myeloid cell line (HL-60 promyelocytes) could be seen at concentrations tenfold lower than those concentrations at which one half of the TNF receptors were occupied. Our data show that significant biologic effects of TNF can occur at low levels of receptor occupancy and resistance to TNF is not related to the absence of TNF receptors on certain myeloid leukemic cell lines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823934

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Signalling pathway of tumor necrosis factor in normal and tumor cells.

Authors:  N Watanabe; H Neda; Y Ohtusuka; H Sone; N Yamauchi; M Maeda; H Kuriyama; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.

Authors:  A A van de Loosdrecht; G J Ossenkoppele; R H Beelen; M G Broekhoven; M M Langenhuijsen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

Authors:  M Brockhaus; H J Schoenfeld; E J Schlaeger; W Hunziker; W Lesslauer; H Loetscher
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Human tumour necrosis factor-alpha (TNF-alpha) directly stimulates arachidonic acid release in human neutrophils.

Authors:  Y H Atkinson; A W Murray; S Krilis; M A Vadas; A F Lopez
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

5.  Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.

Authors:  J A Krosnick; J K McIntosh; J J Mulé; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody.

Authors:  Y Dohi; S Sunada; M Aoki; A Moriguchi; M Okabayashi; M Miyata; H Matsuda
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

7.  Low-affinity receptors for tumour necrosis factor-alpha, interferon-gamma and granulocyte-macrophage colony-stimulating factor are expressed on human placental syncytiotrophoblast.

Authors:  J Hampson; P J McLaughlin; P M Johnson
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

8.  Opposing effects of tumor necrosis factor alpha and leukemia inhibitory factor in lipopolysaccharide-stimulated myelopoiesis.

Authors:  R Kreisberg; M S Detrick; R N Moore
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

9.  Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor.

Authors:  T Hoang; B Levy; N Onetto; A Haman; J C Rodriguez-Cimadevilla
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

Authors:  D W Miles; D Aderka; H Engelmann; D Wallach; F R Balkwill
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.